Advanced Solid Cancers Clinical Trial
Official title:
A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers
This Phase 1/1b, open-label, first-in-human, monotherapy study will be conducted in 2 parts. Part A will consist of the SRF231 monotherapy dose-escalation portion of the study, and will enroll up to 48 patients with advanced solid tumors and hematological cancers. Part B will include monotherapy expansion cohorts in advanced solid and hematologic cancers to further examine SRF231 as monotherapy (100 patients total).
This first-in-human study is designed to evaluate the safety and tolerability of SRF231 as a monotherapy via dose escalation (Part A), and to determine the dose(s) of SRF231 to be further examined in expansion cohorts as monotherapy. The preliminary clinical activity of SRF231 administered as monotherapy will be characterized, along with pharmacokinetics (PK) and pharmacodynamics. In Part B, the safety and tolerability of SRF231 as monotherapy will be evaluated in select patient cohorts of advanced cancers and evaluate clinical activity. The study also is designed to examine the effect of SRF231 monotherapy on peripheral blood immune cell subsets, peripheral blood gene expression, and serum biomarkers ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02792465 -
A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00886782 -
A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03956680 -
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
|
Phase 1 | |
| Terminated |
NCT03254732 -
Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers
|
Phase 1 | |
| Completed |
NCT00478101 -
Opioid Rotation Versus Combination for Chronic Uncontrolled Cancer Pain
|
Phase 2 | |
| Terminated |
NCT00337376 -
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
|
Phase 1 | |
| Completed |
NCT01019941 -
Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer
|
Phase 1 | |
| Completed |
NCT02694822 -
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy
|
Phase 1/Phase 2 |